A carregar...
Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), AOM 400 demonstrated...
Na minha lista:
| Publicado no: | Drugs Context |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Just Medical Media Limited
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5035131/ https://ncbi.nlm.nih.gov/pubmed/27708677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212301 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|